We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current 0KBU market cap is 1.31B. The company's latest EPS is USD -1.8741 and P/E is -5.19.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 111.81M | 73.81M | 0 | 0 | 0 |
| Operating Income | -63.38M | -110.6M | -173.62M | -163.39M | -164.53M |
| Net Income | -84.49M | -138.06M | 194.24M | 47.42M | -117.81M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 136.97M | 181.04M | 419.27M | 590.97M | 378.27M |
| Total Liabilities | 245.99M | 301.79M | 395.49M | 505.29M | 403.25M |
| Total Equity | -109.02M | -120.75M | 23.78M | 85.68M | -24.98M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -60.07M | -100.09M | -109.72M | -86.48M | 74.73M |
| Investing | -3.4M | -67.03M | 193.71M | -127.56M | 27.45M |
| Financing | 60.7M | 174.53M | 6.32M | 124.25M | -106.08M |
| Market Cap | 1.31B |
| Price to Earnings Ratio | -5.19 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 86.11 |
| Price to Book Ratio | -24.48 |
| Dividend Yield | - |
| Shares Outstanding | 62.87M |
| Average Volume (1 week) | 1.98k |
| Average Volume (1 Month) | 5.96k |
| 52 Week Change | 0.00% |
| 52 Week High | 20.79 |
| 52 Week Low | 20.79 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Omeros Corp |
| Address |
3400 capitol blvd se tumwater, washington 98501 |
| Website | https://www.omeros.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
